Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure ...
A new experimental therapy helps restore the heart’s flexibility in models of stiffened heart failure. Michael Gotthardt and his colleagues at the Max Delbrück Center are working with U.S. researchers ...
LOS ANGELES, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced the online publication in Stem Cell Reports of a new study by researchers at the Smidt Heart ...
Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease. It causes the left ventricle to thicken, the ...
Frailty is a condition characterized by increased vulnerability and decline in physical function. It's a growing concern in the aging population, particularly among those with heart disease. A ...
Dying from a broken heart may sound dramatic—but it’s very much a real thing. If you’ve ever experienced a heartbreak so ...
Funded entirely by taxpayer dollars, this first-of-its-kind drug targets cellular metabolism to promote tissue repair of ...
Heart function improved by nearly 50%, and mice moved around 50% more and faster when compared with DMD mice that did not get the drug. These findings were supported by another experiment in which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback